HAZGO

Bedrijvenzone Machelen Cargo 738/2 Office B2. 7, Warehouse 2/C 738/2

1830 Machelen

BE

HAZGO

Foundation date

25/02/2009

Sector

#Supplier & Engineering

Subsector

HAZGO, specializes in the domestic and international issues of dangerous goods logistics. We offer regulatory training, logistics and packaging solutions for the safe and efficient transport of dangerous material. Established in 2009, HAZGO was created to fulfil the demand of a true "One Stop Shop" Dangerous Goods solutions provider. We acknowledge the special needs and demands of this complex "DG" community and provide our customers with a tailored solution. All of our staff have received training from accredited dangerous goods schools in the classification, documentation, packaging and labelling of hazardous materials. HAZGO is unique in its kind as we offer up to date advice on classification, documentation, packaging instructions and regulatory transport requirements. We provide a specialized & tailored service with comprehensive knowledge related to the transport of dangerous goods. With our online web training programme we try to inform and train our customers in Dangerous Goods Awareness. This application makes sure that all staff can be trained in the most effective way. HAZGO has developed a unique "R&D sample management logistics solution" tailored to the specific needs of various R&D industries. This program is created to facilitate the shipping procedures of the R&D departments without compromising the quality of the service. We make sure that samples are packed and shipped in the safest and fastest possible way allowing the industry to retain absolute focus on their main activities with an ease of mind.

Upcoming events

Latest news

  • New way of twisting fibers improves energy storage in wearable devices

    Friday November 22nd 2024

  • Bio Base Europe Pilot Plant successfully commissions a 75,000 L fermenter, demonstrating Vivici’s Vivitein™ BLG technology in industrial-scale precision fermentation

    Thursday November 21st 2024

  • argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

    Wednesday November 20th 2024